Study:
A Phase II Study of Bortezomib (Velcade, PS-341, IND # 58443) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease
Rationale:
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as ifosfamide and vinorelbine, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Bortezomib may help ifosfamide and vinorelbine work better by
making cancer cells more sensitive to the drugs. Giving bortezomib together with ifosfamide
and vinorelbine may kill more cancer cells.
Purpose:
This phase II trial is studying the side effects and how well giving bortezomib
together with ifosfamide and vinorelbine works in treating young patients with Hodgkin`s
lymphoma that is recurrent or did not respond to previous therapy.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Lymphoma |
Drug: bortezomib
Drug: filgrastim
Drug: ifosfamide
Drug: vinorelbine ditartrate
Procedure: chemosensitization/potentiation therapy
Procedure: chemotherapy
Procedure: colony-stimulating factor therapy
Procedure: enzyme inhibitor therapy |
Phase 2 |
Verified by
Children`s Oncology Group
April, 2008
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00381940
Study Type: Interventional
Study Design: Treatment, Open Label
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Terzah M. Horton, MD, PhD., Study Chair
Richard A. Drachtman, MD.,